PuSH - Publication Server of Helmholtz Zentrum München: Preclinical evaluation of human ABCB5+ skin-derived stem cells reveals regenerative mechanisms and prognostic markers in a novel ACLF mouse model.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Neckermann, L.* ; Erdösi, P.* ; Zhang, L. ; Assum, I. ; Dropmann, A.* ; Alaoua, S.* ; Büttner, M. ; Lin, T.* ; Gerstner, M.* ; Ebert, M.P.* ; Bantel, H.* ; Dooley, S.* ; Kluth, A.* ; Menden, M.P. ; Martinez Jimenez, C.P. ; Hammad, S.*

Preclinical evaluation of human ABCB5+ skin-derived stem cells reveals regenerative mechanisms and prognostic markers in a novel ACLF mouse model.

Z. Gastroenterol. 63, e452 - e452 (2025)

Publ. Version/Full Text

DOI

Abstract
Metrics
Extra information

Acute-on-chronic liver failure (ACLF) is a life-threatening condition in chronic liver disease (CLD) patients, often triggered by a precipitating event such as drug or viral infection. High short-term mortality (>30% within 28 days) and the lack of predictive biomarkers or effective therapies demand new preclinical approaches. We established a novel in vivo model using aged Abcb4/Mdr2-/- mice (60–65 weeks), which develop cholestatic CLD [1], in combination with a sublethal dose of hepatotoxic compound (CCl₄) to mimic ACLF. This model reproduces key ACLF features including acute decompensation on CLD background, multi-organ failure, and a critical 24-hour “golden window” predicting divergent outcomes: survival with massive hepatic necrosis and recovery, versus rapid death with minimal necrosis. Using a time-resolved transcriptomic and proteomic profiling, we identified two distinct disease trajectories: a recovery-associated metabolic signature (e.g. Acot1, Hmgcs1, G6pc), and an injury-driven inflammatory signature (e.g. Fgg, Itgam, Cd63). These molecular patterns were conserved in human ACLF datasets and associated with disease severity. ROC analysis revealed nine candidate biomarkers (e.g. Abhd4, Cd14, Slc38a2) for early prognosis. Single-nucleus RNA sequencing uncovered distinct cell populations, including hepatocytes and immune cells with enriched pro-apoptotic and ROS pathways in poor-outcome mice. To address the therapeutic impact, we tested human ABCB5⁺skin-derived mesenchymal stem cells and their macrophage-stimulated secretome. These stem cells enhanced hepatocyte function in vitro (e.g. albumin production), and, applied intravenously, are being evaluated in vivo for their impact on tissue injury, inflammation, regeneration, and survival. Preliminary results indicate a shift in clinical outcome in mice, with an increased survival in the ABCB5⁺ stem cell-treated group, suggesting a potential reduction in the proportion of poor-prognosis cases.

Altmetric